RxDoctor Payments Data

John Moretto, MD

Clinical Pathology/Laboratory Medicine · San Francisco, CANPI 1023086717

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Merck at 38.0% of the total. That places this record below the midpoint for clinical pathology/laboratory medicine clinicians in CA, where the typical reported total is $235.

$51in general payments, 2019–2025

Across 3 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$19
  • Genentech USA, Inc.$16
  • Medline Industries LP$15

What the payments were for

  • Food & beverage$51100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$19
Genentech USA, Inc.1$16
Medline Industries LP1$15

How this compares

$51 in reported general payments places this provider in the 35th percentile of 58 clinical pathology/laboratory medicine providers in California.

See all clinical pathology/laboratory medicine providers in California

Medicare billing

Part B allowed, 2024
$299,545
Medicare patients
2,311
Services billed
7,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology/laboratory medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →